Latuda (Lurasidone HCl) Patent Expiration, LOE Window & CMS Spending

Latuda (Lurasidone HCl) by Sunovion: FDA Orange Book LOE 2031-11-23, 16 AB generics, $74.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSunovion
FDA Application & PathwayN200603 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-11-23
Orange Book Patents (*PED Extensions)10 patents (4 *PED)
Active AB-Rated Generic Competitors16
2024 CMS Total Public Spend$74.8M
2024 Medicare Part D Spend$39.6M
2024 Medicaid Spend$35.1M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.